Followers | 1078 |
Posts | 80316 |
Boards Moderated | 8 |
Alias Born | 03/10/2009 |
Wednesday, November 13, 2019 12:47:23 PM
Alert
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Assertio Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
04545L107
(CUSIP Number)
November 1, 2019
(Date of Event Which Requires Filing of this Statement)
Check the following box to designate the rule pursuant to which the Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 04545L107
1.
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
D. E. Shaw & Co., L.P.
13-3695715
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b)
[ ]
3.
SEC Use Only
4.
Citizenship or Place of Organization
Delaware
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5.
Sole Voting Power
-0-
6.
Shared Voting Power
3,986,178
7.
Sole Dispositive Power
-0-
8.
Shared Dispositive Power
4,059,416
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
4,059,416
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ]
11.
Percent of Class Represented by Amount in Row (9)
5.0%
12.
Type of Reporting Person (See Instructions)
IA, PN
CUSIP No. 04545L107
1.
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
David E. Shaw
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b)
[ ]
3.
SEC Use Only
4.
Citizenship or Place of Organization
United States
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
5.
Sole Voting Power
-0-
6.
Shared Voting Power
3,986,178
7.
Sole Dispositive Power
-0-
8.
Shared Dispositive Power
4,059,416
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
4,059,416
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ]
11.
Percent of Class Represented by Amount in Row (9)
5.0%
12.
Type of Reporting Person (See Instructions)
IN
Item 1.
(a) Name of Issuer
Assertio Therapeutics, Inc.
(b) Address of Issuer's Principal Executive Offices
100 South Saunders Road, Suite 300
Lake Forest, IL 60045
Item 2.
(a) Name of Person Filing
D. E. Shaw & Co., L.P.
David E. Shaw
(b) Address of Principal Business Office or, if none, Residence
The business address for each reporting person is:
1166 Avenue of the Americas, 9th Floor
New York, NY 10036
(c) Citizenship
D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.
David E. Shaw is a citizen of the United States of America.
(d) Title of Class of Securities
Common Stock, $0.0001 par value
(e) CUSIP Number
04545L107
Item 3.
If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
Not Applicable
Item 4.
Ownership
As of November 1, 2019:
(a) Amount beneficially owned:
D. E. Shaw & Co., L.P.:
4,059,416 shares
This is composed of (i) 1,912,174 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 383,943 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 3,944 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 1,759,355 shares under the management of D. E. Shaw Investment Management, L.L.C.
David E. Shaw:
4,059,416 shares
This is composed of (i) 1,912,174 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 383,943 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 3,944 shares in the name of D. E. Shaw Asymptote Portfolios, L.L.C., and (iv) 1,759,355 shares under the management of D. E. Shaw Investment Management, L.L.C.
(b) Percent of class:
D. E. Shaw & Co., L.P.: 5.0%
David E. Shaw: 5.0%
(c) Number of shares to which the person has:
(i) Sole power to vote or to direct the vote:
D. E. Shaw & Co., L.P.: -0- shares
David E. Shaw: -0- shares
(ii) Shared power to vote or to direct the vote:
D. E. Shaw & Co., L.P.: 3,986,178 shares
David E. Shaw: 3,986,178 shares
(iii) Sole power to dispose or to direct the disposition of:
D. E. Shaw & Co., L.P.: -0- shares
David E. Shaw: -0- shares
(iv) Shared power to dispose or to direct the disposition of:
D. E. Shaw & Co., L.P.: 4,059,416 shares
David E. Shaw: 4,059,416 shares
David E. Shaw does not own any shares directly. By virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C. and D. E. Shaw Adviser, L.L.C., which in turn is the investment adviser of D. E. Shaw Asymptote Portfolios, L.L.C., and by virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C. and the managing member of D. E. Shaw Manager, L.L.C., which in turn is the manager of D. E. Shaw Asymptote Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 3,986,178 shares, and the shared power to dispose or direct the disposition of 4,059,416 shares, the 4,059,416 shares as described above constituting 5.0% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 4,059,416 shares.
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
By signing below, each of D. E. Shaw & Co., L.P. and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.
SIGNATURE
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. A Power of Attorney, dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, is attached hereto.
Dated: November 12, 2019
D. E. Shaw & Co., L.P.
By: /s/ Nathan Thomas
Nathan Thomas
Chief Compliance Officer
David E. Shaw
By: /s/ Nathan Thomas
Nathan Thomas
Attorney-in-Fact for David E. Shaw
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent ASRT News
- Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:05 PM
- Sig Kirk Joins Assertio Board of Directors • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Assertio to Present at LD Micro Invitational Conference in New York City • GlobeNewswire Inc. • 04/01/2024 01:00:18 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/11/2024 09:32:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:07:33 PM
- Assertio Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/11/2024 08:01:00 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
- The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Shareholders that lost money on Assertio Holdings, Inc.(ASRT) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:32:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:30:20 PM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) - March 5, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 02/15/2024 10:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:02:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:01:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 12:00:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 11:00:30 PM
- The Gross Law Firm Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT • PR Newswire (US) • 02/09/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:58 PM
- The Gross Law Firm Notifies Shareholders of Assertio Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 5, 2024 - (NASDAQ: ASRT) • PR Newswire (US) • 01/26/2024 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM